FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Wednesday

 

Full steam ahead for Copaxone copies as SCOTUS denies Teva's bid for delay

Last week, generics makers asked the Supreme Court to let them launch their copies of Teva's Copaxone while it hears the Israeli company's appeal over the drug's patents.

Now, they'll likely get that chance. Chief Justice John Roberts rejected Teva's ($TEVA) bid to block competition until the court clash wraps, meaning generics could hit as soon as next month.

Though two generics teams--Novartis' ($NVS) Sandoz unit and Momenta Pharmaceuticals ($MNTA), and Mylan ($MYL) and India's Natco Pharma--are now free to move forward, they'll have to fork over infringement damages if Teva ultimately prevails in court. And that was enough to convince Roberts a court-ordered stay was unnecessary, Bloomberg reports.

"Given the availability of that remedy, the extraordinary relief Teva seeks is unwarranted," he wrote in a one-paragraph opinion, as quoted by the news service.

It's not a risk Teva wanted to take. That's because the price concessions it will be forced to make to compete with generics will be "for all practical purposes irreversible." The multiple sclerosis med accounts for more than half the drugmaker's profit, and it's milking this pre-generics window to switch as many patients as possible over to a new, long-lasting formulation of the drug.

Story Source: The above story is based on materials provided by FIERCEPHARMA
Note: Materials may be edited for content and length

Labels:



Go to Newer News Go to Older News